This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical Third Quarter 2021 Results Conference Call. As a reminder, this conference is being recorded. At this time, I would like to introduce Jason Finkelstein, Investor Relations. Please go ahead.
spk03: Good afternoon. This is Jason Finkelstein of Argo Partners, the Investor Relations Representative for Rockwell Medical. Joining me from Rockwell Medical on today's call are Dr. Russell Ellison, President and Chief Executive Officer, and Russell Skipstead, Executive Vice President, Chief Financial Officer, and Chief Business Officer. Dr. Mark Hoffman, Chief Medical Officer, and Tim Cole, Senior Vice President of Sales and Marketing, will be available for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Within the meeting on the federal securities laws, including but not limited to, the types of statements identified as forward-looking in our quarterly report on Form 10Q that was filed today, our annual report on Form 10K that was filed on March 31st, 2021, and our subsequent periodic reports filed with the SEC, which will be available on our website in the investor relations section. These statements are subject to risks and uncertainties that can cause actual results to differ. Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. This conference call can be accessed on Rockwell Medical's Investor Relations webpage. This call is being recorded for audio rebroadcast and can also be accessed on the same webpage. At this time, I would like to turn the conference call over to Rockwell Medical's Chief Executive Officer, Dr. Russell Ellison.
spk13: Russell? Thank you, Jason. Good afternoon, and thank you for joining us. In the third quarter of 2021, we continued to progress our strategy with improvements on the solid foundation and reputation of our dialysis business, combined with advancement in the development of the RFPC platform outside of dialysis. Driven by returning growth in dialysis concentrates products, Rockwell delivered a strong third quarter, which saw an increase in net sales versus both the second quarter of 2021 and the third quarter of last year. Our concentrates business continues to perform to our expectations both domestically and internationally. We're in the process of exploring expanding this business geographically in the U.S. We're very pleased to have achieved an important development milestone with the submission of an IND for FPC for patients receiving infusion therapy at home. As you may recall in June, we submitted a pre-IND meeting request to FDA to gain feedback on our Phase II clinical trial proposal. The proposed randomized placebo-controlled study is expected to evaluate two dosing regimens of FPC versus placebo, one for the treatment of iron deficiency anemia and the other for the maintenance of hemoglobin. We have initiated preliminary study activities in anticipation of the clearance of our IND on or about December 9. Home infusion therapy is a service model that allows patients requiring regular infusions of medications to be treated in the comfort of their own homes. For clarity, when we refer to home infusion, we are not referring to home hemodialysis. This is a large, rapidly growing segment of healthcare with more than 3.2 million patients as of 2019. Many patient groups requiring home infusion therapies suffer from chronic diseases that are associated with a high incidence of iron deficiency and anemia. For example, it's estimated that 40 to 55% of all home parenteral nutrition patients are iron deficient. Current treatment patterns can be inadequate for patients on home infusion therapy with iron deficiency anemia, causing them to suffer extreme fatigue and can result in serious health risks, such as poor immune function and heart failure. While it's premature to estimate the market for FPC in these patient populations, we believe that up to 700,000 patients receiving home infusion therapy in the U.S. may benefit from a safe and effective way to treat iron deficiency, which may suggest an addressable market opportunity of up to $600 million. We'll have more to say about the market opportunity in home infusion after our IND clears and we begin our clinical trials. I'll now turn to our recent business development and accomplishments as they pertain to our existing dialysis business, which is comprised of revenue from both Triferic and our concentrates. Our partners continue to progress in their efforts to gain regulatory approval and begin commercialization in FPC in their respective countries. We believe international sales in Triferic will be a strong source of revenue and value in the coming years. as dialysis payer models in many countries outside of the U.S. are more accommodating for innovative products. We recently presented new real-world evidence from an observational analysis program at multiple clinics, which are part of a mid-sized dialysis organization, or MDO, at the American Society of Nephrology Kidney Week 2021 in San Diego, California. Results confirm findings from our prior real-world evidence publication, foremost that the integration of TRIFERIC into anemia management protocols results in the reduction of IV iron utilization and total iron usage. The results are relevant not only for patients and caregivers, but for dialysis clinics and the medical community. And we believe that the results can further strengthen TRIFERIC's position as an important part of the treatment arsenal for patients on hemodialysis. Triceric revenue in the third quarter was essentially flat versus the second quarter. One of our customers was acquired and allowed their contract with us to expire. But we were able to largely offset these losses by securing Triceric agreements with new clinics at an improved average selling price, or ASP, which stabilized revenue for the quarter. Triceric continues to experience headwinds in our efforts to accelerate adoption in the U.S. dialysis market. Changes in medical practice and dialysis are slow to occur and are evidence-based. And, as previously disclosed, Triferic is sold into a heavily competitive space with capitated reimbursement and bundled offerings from our competitors. In the face of these continued headwinds, we have decided to shift our commercial strategy for Triferic and Triferic Avenue in the United States. As part of this initiative, we've adjusted our sales and marketing efforts, and are working to find a sales partner to expand our commercial efforts within the United States. We expect that alignment with a partner will bring commercial strength needed to more effectively compete in the environment of consolidated for-profit dialysis provider organizations and large, vertically integrated competitive suppliers. We continue to believe Triferic is a safe, efficacious, important, and innovative therapeutic for the maintenance of hemoglobin in patients on hemodialysis. While we are committed to the continued commercialization of Triferic in the U.S., we will be intentional about future commercial spending as we acknowledge the challenges we are facing in the present environment. With that, I'll turn the call to Russell Skifstead for a brief financial overview. Russell?
spk15: Thanks, Russell. We ended the third quarter of 2021 with cash, cash equivalents and investments of approximately $33.2 million, which was in line with our expectations and which we believe keeps us in a position to drive our company's strategic initiatives. During the third quarter, our net sales were $16 million, compared to $15.3 million in the third quarter of 2020 and $15.1 million in the second quarter of this year. Net sales of hemodialysis concentrates were approximately $15.7 million during the quarter, which was about $713,000 higher compared to the third quarter of the prior year, and about $845,000 higher in the second quarter of this year. We're starting to see the expected uptick in concentrate sales as the impact of COVID subsides, with increased sales both domestically and internationally. Total sales of Triferic were approximately $280,000 for the quarter, which was roughly flat versus the sales of Triferic in the third quarter of 2020 and the second quarter of 2021. Net cash used in operating activities was $7.1 million for the quarter, which compared to $4.9 million in the second quarter, Our third quarter cash was higher than normal due to both seasonal and timing factors. Our use of cash in the third quarter was in line with our expectations, reflecting seasonal timing, some non-recurring costs related to our cost savings efforts, the impact of COVID, and the beginning of the impact of some of our efficiency initiatives. We have completed most of our analysis related to our supply chain and logistics projects. and are now prioritizing the short, mid, and longer-term initiatives that we intend to pursue. I expect to have more to share about this after the first of the year. I'll now turn the call back to Russell Ellison for his closing remarks. Russell?
spk13: Thanks, Russell. I'll conclude by saying that considering the large opportunities ahead of us and the steady revenue we have seen from our dialysis business, which includes sales of our concentrate products, I consider Rockwell Medical very much a development stage biopharmaceutical company with a stable base of revenue generating products. We're working to advance our dialysis business alongside the exciting opportunity to develop FPC for home infusion patients with iron deficiency anemia and the potential program in hospitalized patients with acute heart failure. Thank you for joining our call today. and for your interest in Rockwell Medical. I want to thank our shareholders for your patience and belief in our efforts to unlock the value of this company. I'll now turn the line over to the operator for questions. Thank you.
spk06: And thank you. As a reminder to ask a question, you'll need to press star 1 on your telephone. To withdraw your question, press the pound key. Please stand by, we'll compile the Q&A roster. And our first question comes from Ram Telabudju with HC Wainwright. Your line is now open. Thank you so much. Can you hear me?
spk05: Yes, we can hear you, Ram. Great, thanks. So, firstly, I was wondering if you could talk a little bit about The clinical development initiatives and the context in which you anticipate those are likely to be carried out given all of the ongoing uncertainties surrounding the evolution of the pandemic, the well-documented impact that that has had on other clinical development programs. How do you see the pandemic impacting your envisaged clinical development activities Do you see that impact effectively becoming muted in the course of the coming months?
spk13: That's a great question, Ron, and I'll take a stab at it first and then turn it over to Mark Hoffman, our chief medical officer. Ironically, the first development program we're embarking on is the use of ferric pyrophosphate citrate to treat iron deficiency anemia in the home infusion settings. And in the home infusion setting, you really don't have, ironically, the constraints of bringing people into a clinic to get their medication as part of a trial. They get this at home. And the visits of the home health care aide to set this up is basically part of their routine management. So, ironically, doing a home infusion trial in the COVID pandemic, even though the pandemic is waning to some extent, is remarkably, you know, largely unaffected. So we're fortunate that we're doing it, that we're doing that trial in this context. Mark, do you want to comment a little more on that?
spk11: Sure, Russell.
spk14: So I would agree with absolutely everything that Russell has just stated and just take this step further and say that, number one, The pandemic is where the home infusion visit is actually one of the perceived benefits of this study is not having to go into a clinic or a hospital to receive therapy. So that's one of the things that we see downstream as a benefit. The other is that coming in where we are on the pandemic, it's actually given a number of the clinical research organizations the opportunity to build and fine-tune this type of study design where the patients are being seen and there's more remote data entry and less touch for data collection and patient management. So we're actually benefiting from this in many ways.
spk13: And I would add on the heart failure trial, first we have to have a little discussion with FDA particularly about their requirements for the reduced time requirements for short-term trials, for short-term treatments and acute heart failure. They put out guidance that you don't really require, you're not really required to show an impact on mortality or the lack of an impact, and that makes the overall program much more tractable. But we do want to confirm that with FDA before we start the heart failure trial. I would say one impact of the pandemic is that, you know, face-to-face meetings with FDA just don't happen anymore. At least they haven't been. And, you know, you can get a phone call, which is not bad. But by and large, communication is by correspondence. So I think, you know, I'm quite used to actually, you know, going down to Washington and to Bethesda and sitting with them. And that's been, you know, a little different now. I don't really know what the overall impact has been, but it certainly is different. So that's really it. And even when we do congestive heart failure, that will be in hospitalized patients. So you really have to be there. And hopefully by the time we start that trial, we'll be more out of the woods than we are now with respect to the impact of COVID on hospitals.
spk05: That's very helpful, very nuanced answer. Secondly, I was wondering, in the context of your shift in strategy and your seeking of a partner, is this going to be a situation in which there's maybe a bifurcated scenario, invisible, where you continue the development in these indications for which you expect to conduct clinical development programs? but a partner potentially takes on the responsibility of moving forward with the commercially available product offerings? Or is it a situation where you are envisaging a partner effectively coming in and supporting both aspects, the clinical development programs as well as the commercial product offerings?
spk13: That's a really good point, Ram, and I'm sorry we weren't as clear as we could have been about that. But basically, yeah, we're focused on the commercialization of TriFerric in the United States. We're not anticipating at this point partnering our two development programs. You know, post-Phase II, when we have completed Phase II data, that would be certainly a very good option for the heart failure indication. And, you know, I don't know at this point. I can't really say about home infusion. It depends on how big that Phase III program would have to be, et cetera. But right now, what we've been referring to in the call today is partnering the commercialization of Triferic in the U.S.
spk05: Okay, and lastly, prior announcements have involved quite a number of ex-U.S., ex-European international developments, and there's clearly interest in and relevance of Triferic, Triferic Avenue in those markets. So I was wondering if you are anticipating any noteworthy developments on the international front, whether those are from a commercial launch or a partnership deal announcement standpoint, and with what timing kinetics those might potentially accrue, those might potentially mature. If you have any color on which specific region, whether those are Asia-Pac or LATAM, Far East, et cetera, you know, there might be some additional value-driving catalyst. If you could comment on that, please.
spk10: That's a great point.
spk15: R2, do you want to address this? Sure. Sure, I can take that. Thanks, Ram. Thanks for the question. I would say that it's a big question. As Russell mentioned earlier on in his prepared comments, it's interesting because in some of the countries outside of the U.S., actually, we think there are better markets and way better reimbursement than we would have in the U.S. For instance, China, which is the largest dialysis market in the world. And so both, you know, with India and with China, the programs are underway. They're on schedule with, you know, their plans. We would expect to see data from the clinical trial in China. I think we're looking at probably the first half of 2023, and then from there it goes through the regulatory process before launch. But I think in terms of timing when we're going to hear something, I would think that, you know, we're waiting for a word from the Korean authorities on the NDA submission that our partner JAIL submitted earlier this year. And that, I would think, would probably be our first product launch, provided they get the okay from the authorities. So I know we're doing a lot of preparation work right now behind the scenes, trying to get ready for that launch in anticipation of that launch. So we'll keep our fingers crossed.
spk01: Thank you.
spk06: And thank you. This concludes the Q&A session. Now I'll turn the line back to Dr. Ellison for closing remarks.
spk13: Well, thank you all for joining us on this call, and I just want to thank you for your continued support and faith in this company and our efforts to be successful. And I look forward to Our next call with you in the next quarter. Thanks very much.
spk06: This concludes today's conference call. Thank you for participating. You may now disconnect. Thank you. Thank you. Thank you. Bye.
spk07: Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical Third Quarter 2021 Results Conference Call. As a reminder, this conference is being recorded at this time. I would like to introduce Jason Finkelstein, Investor Relations. Please go ahead.
spk03: Good afternoon. This is Jason Finkelstein of Argo Partners, the Investor Relations Representative for Rockwell Medical. Joining me from Rockwell Medical on today's call are Dr. Russell Ellison, President and Chief Executive Officer, and Russell Skipstead, Executive Vice President, Chief Financial Officer, and Chief Business Officer. Dr. Mark Hoffman, Chief Medical Officer, and Tim Cole, Senior Vice President of Sales and Marketing, will be available for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Within the meeting on the federal securities laws, including but not limited to, the types of statements identified as forward-looking in our quarterly report on Form 10Q that was filed today, our annual report on Form 10K that was filed on March 31st, 2021, and our subsequent periodic reports filed with the SEC, which will be available on our website in the investor relations section. These statements are subject to risks and uncertainties that can cause actual results to differ. Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. This conference call can be accessed on Rockwell Medical's Investor Relations webpage. This call is being recorded for audio rebroadcast and can also be accessed on the same webpage. At this time, I would like to turn the conference call over to Rockwell Medical's Chief Executive Officer, Dr. Russell Ellison. Russell?
spk13: Thank you, Jason. Good afternoon, and thank you for joining us. In the third quarter of 2021, we continued to progress our strategy with improvements on the solid foundation and reputation of our dialysis business, combined with advancement in the development of the RFPC platform outside of dialysis. Driven by returning growth in dialysis concentrates products, Rockwell delivered a strong third quarter, which saw an increase in net sales versus both the second quarter of 2021 and the third quarter of last year. Our concentrates business continues to perform to our expectations both domestically and internationally. We're in the process of exploring expanding this business geographically in the U.S. We're very pleased to have achieved an important development milestone with the submission of an IMD for FPC for patients receiving infusion therapy at home. As you may recall in June, we submitted a pre-IND meeting request to FDA to gain feedback on our Phase II clinical trial proposal. The proposed randomized placebo-controlled study is expected to evaluate two dosing regimens of FPC versus placebo, one for the treatment of iron deficiency anemia and the other for the maintenance of hemoglobin. We have initiated preliminary study activities in anticipation of the clearance of our IND on or about December 9. Home infusion therapy is a service model that allows patients requiring regular infusions of medications to be treated in the comfort of their own homes. For clarity, when we refer to home infusion, we are not referring to home hemodialysis. This is a large, rapidly growing segment of healthcare with more than 3.2 million patients as of 2019. Many patient groups requiring home infusion therapies suffer from chronic diseases that are associated with a high incidence of iron deficiency and anemia. For example, it's estimated that 40 to 55% of all home parenteral nutrition patients are iron deficient. Current treatment patterns can be inadequate for patients on home infusion therapy with iron deficiency anemia, causing them to suffer extreme fatigue and can result in serious health risks, such as poor immune function and heart failure. While it's premature to estimate the market for FPC in these patient populations, we believe that up to 700,000 patients receiving home infusion therapy in the U.S. may benefit from a safe and effective way to treat iron deficiency, which may suggest an addressable market opportunity of up to $600 million. We'll have more to say about the market opportunity in home infusion after our IND clears and we begin our clinical trials. I'll now turn to our recent business development and accomplishments as they pertain to our existing dialysis business, which is comprised of revenue from both Triferic and our concentrates. Our partners continue to progress in their efforts to gain regulatory approval and begin commercialization in FPC in their respective countries. We believe international sales in Triferic will be a strong source of revenue and value in the coming years. as dialysis payer models in many countries outside of the U.S. are more accommodating for innovative products. We recently presented new real-world evidence from an observational analysis program at multiple clinics, which are part of a mid-sized dialysis organization, or MDO, at the American Society of Nephrology Kidney Week 2021 in San Diego, California. Results confirmed findings from our prior real-world evidence publications, foremost that the integration of TRIFERIC into anemia management protocols results in the reduction of IV iron utilization and total iron usage. The results are relevant not only for patients and caregivers, but for dialysis clinics and the medical community. And we believe that the results can further strengthen TRIFERIC's position as an important part of the treatment arsenal for patients on hemodialysis. Triceric revenue in the third quarter was essentially flat versus the second quarter. One of our customers was acquired and allowed their contract with us to expire. But we were able to largely offset these losses by securing Triceric agreements with new clinics at an improved average selling price, or ASP, which stabilized revenue for the quarter. Triceric continues to experience headwinds in our efforts to accelerate adoption in the U.S. dialysis market. Changes in medical practice and dialysis are slow to occur and are evidence-based. And, as previously disclosed, Triferic is sold into a heavily competitive space with capitated reimbursement and bundled offerings from our competitors. In the face of these continued headwinds, we have decided to shift our commercial strategy for Triferic and Triferic Avenue in the United States. As part of this initiative, we've adjusted our sales and marketing efforts, and are working to find a sales partner to expand our commercial efforts within the United States. We expect that alignment with a partner will bring commercial strength needed to more effectively compete in the environment of consolidated for-profit dialysis provider organizations and large, vertically integrated competitive suppliers. We continue to believe Triferic is a safe, efficacious, important, and innovative therapeutic for the maintenance of hemoglobin in patients on hemodialysis. While we are committed to the continued commercialization of Triferic in the U.S., we will be intentional about future commercial spending as we acknowledge the challenges we are facing in the present environment. With that, I'll turn the call to Russell Skifstad for a brief financial overview. Russell?
spk15: Thanks, Russell. We ended the third quarter of 2021 with cash cash equivalents and investments of approximately $33.2 million, which was in line with our expectations and which we believe keeps us in a position to drive our company's strategic initiatives. During the third quarter, our net sales were $16 million, compared to $15.3 million in the third quarter of 2020 and $15.1 million in the second quarter of this year. Net sales of hemodialysis concentrates were approximately $15.7 million during the quarter, which was about $713,000 higher compared to the third quarter of the prior year, and about $845,000 higher in the second quarter of this year. We're starting to see the expected uptick in concentrate sales as the impact of COVID subsides, with increased sales both domestically and internationally. Total sales of Triferic were approximately $280,000 for the quarter, which was roughly flat versus the sales of Triferic in the third quarter of 2020 and the second quarter of 2021. Net cash used in operating activities was $7.1 million for the quarter, which compared to $4.9 million in the second quarter, Our third quarter cash was higher than normal due to both seasonal and timing factors. Our use of cash in the third quarter was in line with our expectations, reflecting seasonal timing, some non-recurring costs related to our cost savings efforts, the impact of COVID, and the beginning of the impact of some of our efficiency initiatives. We have completed most of our analysis related to our supply chain and logistics projects. and are now prioritizing the short, mid, and longer-term initiatives that we intend to pursue. I expect to have more to share about this after the first of the year. I'll now turn the call back to Russell Ellison for his closing remarks. Russell?
spk13: Thanks, Russell. I'll conclude by saying that considering the large opportunities ahead of us and the steady revenue we have seen from our dialysis business, which includes sales of our concentrate products, I consider Rockwell Medical very much a development stage biopharmaceutical company with a stable base of revenue generating products. We're working to advance our dialysis business alongside the exciting opportunity to develop FPC for home infusion patients with iron deficiency anemia and the potential program in hospitalized patients with acute heart failure. Thank you for joining our call today. and for your interest in Rockwell Medical. I want to thank our shareholders for your patience and belief in our efforts to unlock the value of this company. I'll now turn the line over to the operator for questions. Thank you.
spk06: And thank you. As a reminder to ask a question, you'll need to press star 1 on your telephone. To withdraw your question, press the pound key. Please stand by. We compile the Q&A roster. And our first question comes from Ram Telabudju with HC Wainwright. Your line is now open. Thank you so much. Can you hear me?
spk05: Yes, we can hear you, Ram. Great, thanks. So, firstly, I was wondering if you could talk a little bit about The clinical development initiatives and the context in which you anticipate those are likely to be carried out given all of the ongoing uncertainties surrounding the evolution of the pandemic, the well-documented impact that that has had on other clinical development programs. How do you see the pandemic impacting your envisaged clinical development activities Do you see that impact effectively becoming muted in the course of the coming months?
spk13: That's a great question, Ron, and I'll take a stab at it first and then turn it over to Mark Hoffman, our chief medical officer. Ironically, the first development program we're embarking on is the use of ferric pyrophosphate citrate to treat iron deficiency anemia in the home infusion setting And in the home infusion setting, you really don't have, ironically, the constraints of bringing people into a clinic to get their medication as part of a trial. They get this at home. And the visits of the home health care aide to set this up is basically part of their routine management. So, ironically, doing a home infusion trial in the COVID pandemic, even though the pandemic is waning to some extent, is remarkably, you know, largely unaffected. So we're fortunate that we're doing it, that we're doing that trial in this context. Mark, do you want to comment a little more on that?
spk11: Sure, Russell.
spk14: So I would agree with absolutely everything that Russell has just stated and just take this step further and say that, number one, The pandemic is where the home infusion visit is actually one of the perceived benefits of this study is not having to go into a clinic or a hospital to receive therapy. So that's one of the things that we see downstream as a benefit. The other is that coming in where we are on the pandemic, it's actually given a number of the clinical research organizations the opportunity to build and fine-tune this type of study design where the patients are being seen and there's more remote data entry and less touch for data collection and patient management. So we're actually benefiting from this in many ways.
spk13: And I would add on the heart failure trial, first we have to have a little discussion with FDA particularly about their requirements for the reduced time requirements for short-term trials, for short-term treatments and acute heart failure. They put out guidance that you don't really require to show an impact on mortality or the lack of an impact, and that makes the overall program much more tractable. But we do want to confirm that with FDA before we start the heart failure trial. I would say one impact of the pandemic is that, you know, face-to-face meetings with FDA just don't happen anymore. At least they haven't been. And, you know, you can get a phone call, which is not bad. But by and large, communication is by correspondence. So I think, you know, I'm quite used to actually, you know, going down to Washington and to Bethesda and sitting with them. And that's been, you know, a little different now. I don't really know what the overall impact has been, but it certainly is different. So that's really it. And even when we do congestive heart failure, that will be in hospitalized patients. So you really have to be there. And hopefully by the time we start that trial, we'll be more out of the woods than we are now with respect to the impact of COVID on hospitals.
spk05: That's very helpful, very nuanced answer. Secondly, I was wondering, in the context of your shift in strategy and your seeking of a partner, is this going to be a situation in which there's maybe a bifurcated scenario, invisible, where you continue the development in these indications for which you expect to conduct clinical development programs? but a partner potentially takes on the responsibility of moving forward with the commercially available product offerings? Or is it a situation where you are envisaging a partner effectively coming in and supporting both aspects, the clinical development programs as well as the commercial product offerings?
spk13: That's a really good point, Rahm, and I'm sorry we weren't as clear as we could have been about that. But basically, yeah, we're focused on the commercialization of Triferic in the United States. We're not anticipating at this point partnering our two development programs. You know, post-Phase II, when we have completed Phase II data, that would be certainly a very good option for the heart failure indication. And, you know, I don't know at this point. I can't really say about home infusion. It depends on how big that Phase III program would have to be, et cetera. But right now, what we've been referring to in the call today is partnering the commercialization of Triferic in the U.S.
spk05: Okay, and lastly, prior announcements have involved quite a number of ex-U.S., ex-European international developments, and there's clearly interest in and relevance of Triferic, Triferic Avenue in those markets. So I was wondering if you are anticipating any noteworthy developments on the international front, whether those are from a commercial launch or a partnership deal announcement standpoint, and with what time frame, with what timing kinetics those might potentially accrue, those might potentially mature. If you have any color on which specific region, whether those are Asia-Pac or LATAM, Far East, et cetera, you know, there might be some additional value-driving catalysts. If you could comment on that, please.
spk10: Great point.
spk15: R2, do you want to address this? Sure. Sure, I can take that. Thanks, Ram. Thanks for the question. I would say that it's a big question. As Russell mentioned earlier on in his prepared comments, it's interesting because in some of the countries outside of the U.S., actually we think there are better markets and way better reimbursement than we would have in the U.S. For instance, China, which is the largest dialysis market in the world. And so both with India and with China, the programs are underway. They're on schedule with their plans. We would expect to see data from the clinical trial in China. I think we're looking at probably the first half of 2023, and then from there it goes through the regulatory process before launch. But I think in terms of timing when we're going to hear something, I would think that we're waiting for word from the Korean authorities on the NDA submission that our partner, JAIL, submitted earlier this year. And that, I would think, would probably be our first product launch, provided they get the okay from the authorities. So I know we're doing a lot of preparation work right now behind the scenes, trying to get ready for that launch in anticipation of that launch. So we'll keep our fingers crossed.
spk01: Thank you.
spk06: And thank you. This concludes the Q&A session. Now I'll turn the line back to Dr. Ellison for closing remarks.
spk13: Well, thank you all for joining us on this call, and I just want to thank you for your continued support and faith in this company and our efforts to be successful. And I look forward to Our next call with you for the next quarter. Thanks very much. This concludes today's conference call.
spk06: Thank you for participating. You may now disconnect.
Disclaimer